Targeted chemoradiation in metastatic colorectal cancer: A phase i trial of 131i-hua33 with concurrent capecitabine

Journal of Nuclear Medicine

Volumn 55, Issue 4, 2014, Pages 534-539

  Herbertson, Rebecca A ^a   Tebbutt, Niall C ^a,b   Lee, Fook Thean ^a,b   Gill, Sanjeev ^a   Chappell, Bridget ^b   Cavicchiolo, Tina ^a   Saunder, Tim ^b   O'Keefe, Graeme J ^a,b   Poon, Aurora ^b   Lee, Sze Ting ^a   Murphy, Roger ^a   Hopkins, Wendie ^a   Scott, Fiona E ^a   Scott, Andrew M ^a,b  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chemotherapy; Colorectal cancer; Radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; IODINE HUMANIZED A33 ANTIBODY I 131; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; IMMUNOGENICITY; ISOTOPE LABELING; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RETROSTERNAL PAIN; THORAX PAIN; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

CHEMOTHERAPY; COLORECTAL CANCER; RADIOIMMUNOTHERAPY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; ISOTOPE LABELING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PATIENT SELECTION; RADIOMETRY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84901363772     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.132761     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
3. Wu C, Goldberg RM. Colorectal cancer in 2012: revisiting landmark trials and identifying new therapies. Nat Rev Clin Oncol. 2013;10:71-72.
4. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
5. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143-4149.
6. Garinchesa P, Sakamoto J, Welt S, Real FX, Rettig WJ, Old LJ. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibodybased therapy. Int J Oncol. 1996;9:465-471.
7. Sakamoto J,KojimaH,Kato J, HamashimaH, Suzuki H. Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibodybased imaging and treatment in gastrointestinal cancer. Cancer Chemother Pharmacol. 2000;46(suppl):S27-S32.
8. Daghighian F, Barendswaard E, Welt S, et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med. 1996;37:1052-1057.
9. King DJ, Antoniw P, Owens RJ, et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 1995; 72:1364-1372.
10. Scott AM, Lee F-T, Jones R, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res. 2005;11:4810-4817.
11. Welt S, Ritter G, Williams C Jr, et al. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res. 2003;9:1338-1346.
12. Welt S, Ritter G, Williams C Jr, et al. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2003;9:1347-1353.
13. Chong G, Lee FT, Hopkins W, et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005;11:4818-4826.
14. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol. 2005;23:5620-5627.
15. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620-4625.
16. Peeters KCMJ, van de Velde CJH, Leer JWH, et al. Late side effects of shortcourse preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199-6206.
17. Krishnan S, Janjan NA, Skibber JM, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66:762-771.
18. Tschmelitsch J, Barendswaard E, Williams C Jr, et al. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res. 1997;57:2181-2186.
19. Lee FT, Hall C, Rigopoulos A, et al. Immuno-PET of human colon xenograftbearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med. 2001;42:764-769.
20. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
21. Ritter G, Cohen LS, Williams C Jr., Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 2001;61:6851-6859.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
23. Kinuya S, Yokoyama K, Tega H, et al. Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts. J Cancer Res Clin Oncol. 1999;125:630-636.
24. Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med. 2006;47:716-725.
25. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res. 2000;6:3621-3628.
26. Kelly MP, Lee ST, Lee FT, et al. Therapeutic efficacy of 177Lu-CHX-A'-DTPAhu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate. 2009;69:92-104.
27. Al-Ejeh F, Shi W, Miranda M, et al. Treatment of triple negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitising chemotherapy and PARP inhibitor. J Nucl Med. 2013;54:913-921.
28. Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW. Evaluation of platinum chemotherapy in combination with HER2-targeted a-particle radiation. Cancer Biother Radiopharm. 2013;28:441-449.
29. Richman CM, DeNardo SJ, O'Donnell RT, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to Indium-111/Yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human antimouse antibody. Clin Cancer Res. 2005;11:5920-5927.
30. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm. 2001; 16:305-315.
31. Wong JYC, Shibata S, Williams LE, et al. A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003;9:5842-5852.
32. Forero A, Meredith RF, Khazaeli MB, et al. Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. Cancer Biother Radiopharm. 2005;20:467-478.
33. Ocean AJ, Pennington KL, Guarino MJ, et al. Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial. Cancer. 2012;118:5497-5506.
34. Tomblyn MB, Katin MJ, Wallner PE. The new golden era for radioimmunotherapy: not just for lymphomas anymore. Cancer Control. 2013;20:60-71.
35. Hoff PM, Pazdur R, Lassere Y, et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol. 2004; 22:2078-2083.
36. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278-287.
37. Press OW, Unger JM, Rimsza LM, et al. Phase III randomised intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-Hodgkins lymphoma: SWOG S0016. J Clin Oncol. 2013;31:314-320.
38. Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800-816.
39. Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med. 2012;42:190-207.
40. Tagawa ST, Milowsky MI, Morris MJ, et al. Phase II of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182-5191.